Antibody Contract Manufacturing Market Size Worth USD 44.96 billion by 2034 | CAGR: 9.96%

The antibody contract manufacturing market size is expected to reach USD 44.96 billion by 2034, according to a new study by Polaris Market Research. The report “Antibody Contract Manufacturing Market Size, Share, Trends, Industry Analysis Report: By Product (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, and Others), By Source, By Therapeutic Area, By End User, and By Region – Market Forecast, 2026–2034” gives a detailed insight into current market dynamics and provides analysis on future market growth.

Antibody contract manufacturing refers to outsourced services dedicated to the large-scale production of monoclonal and polyclonal antibodies for therapeutic, diagnostic, and research purposes. These services are widely used by pharmaceutical and biotechnology companies to support drug development, vaccine production, and diagnostic assay manufacturing.

Antibody contract manufacturing involves outsourcing the production of monoclonal, polyclonal, and bispecific antibodies, enabling biopharmaceutical companies to meet growing therapeutic and diagnostic demand. These services are carried out under stringent regulatory and quality guidelines to ensure high yield, product consistency, and clinical-grade safety.

The market growth is fueled by the increasing global incidence of cancer and other chronic diseases, which is driving demand for targeted antibody-based therapies. Rising global R&D expenditure in oncology and immunology is further boosting the development of next-generation biologics.

Key Takeaways

• North America led with a 35.2% share in 2025. This is attributed to its strong biopharmaceutical production capabilities.
• Asia Pacific is projected to account for a 12.7% CAGR. This is driven by the rapid expansion of the regional biotechnology sector.
• Europe accounted for a 27.6% share in 2025. Growing investment in biologics and advanced therapeutic research contributes to the regional growth.
• The monoclonal antibodies segment led with a 74.8% share in 2025. This is due to its extensive clinical use across infectious disease therapies.
• The bispecific antibodies segment is projected to grow at a 14.6% CAGR. The dual-targeting capabilities of bispecific antibodies enhance therapeutic efficacy.
• The mammalian segment held a 58.9% share in 2025. The segment’s dominance is due to its ability to produce complex antibodies with high efficacy.
• The oncology segment led with a 46.7% market share in 2025. This is due to the dominance of monoclonal and bispecific antibodies in cancer immunotherapy.
• The research laboratories segment is projected to grow at a 11.8% CAGR. The segment’s growth is driven by the expansion of academic and preclinical research in antibody engineering.
• A few of the key market players include AbbVie Inc.; AGC Biologics; Boehringer Ingelheim International GmbH; Catalent, Inc.; Charles River Laboratories; Fujifilm Diosynth Biotechnologies; Lonza Group AG; Lotte Biologics; mAbxience; Merck Group; Rentschler Biopharma SE; Samsung Biologics; Shilpa Medicare Ltd.; Thermo Fisher Scientific Inc.; and WuXi Biologics.

Request a free sample copy or read the full market insights: Antibody Contract Manufacturing Market Report

Polaris Market Research has segmented the market report on the basis of product, source, technology, therapeutic area, end user, and region:

By Product Outlook (Revenue, USD Billion, 2021–2034)

• Monoclonal Antibodies
• Polyclonal Antibodies
• Bispecific Antibodies
• Others

By Source Outlook (Revenue, USD Billion, 2021–2034)

• Mammalian
• Microbial

By Technology Outlook (Revenue, USD Billion, 2021–2034)

• Recombinant DNA Technology
• Hybridoma Technology
• Phage Display Technology
• Cell-Free Synthesis

By Therapeutic Area (Revenue, USD Billion, 2021–2034)

• Oncology
• Neurology
• Cardiology
• Infectious Diseases
• Other Therapeutic Areas

By End User (Revenue, USD Billion, 2021–2034)

• Biopharmaceutical Companies
• Research Laboratories
• Others

By Regional Outlook (Revenue, USD Billion, 2021–2034)

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Netherlands
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Malaysia
  • South Korea
  • Indonesia
  • Australia
  • Vietnam
  • Rest of Asia Pacific
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Israel
  • South Africa
  • Rest of Middle East & Africa
• Latin America
  • Mexico
  • Brazil
  • Argentina
  • Rest of Latin America